• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by Klotho Neurosciences Inc.

    12/15/25 12:15:09 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KLTO alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: December 12, 2025 4:30 P.M.
    Form: S-1
    CIK: 0001907223
    Company Name: Klotho Neurosciences, Inc.
    File Number: 333-291990
    Get the next $KLTO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KLTO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KLTO
    SEC Filings

    View All

    Klotho Neurosciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Greenland Mines Ltd (0001907223) (Filer)

    3/16/26 12:32:05 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Klotho Neurosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Greenland Mines Ltd (0001907223) (Filer)

    3/12/26 4:00:51 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Klotho Neurosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - Klotho Neurosciences, Inc. (0001907223) (Filer)

    3/10/26 5:00:26 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML

    Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it changed its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open today, Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The Company will hol

    3/12/26 10:27:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026

    Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 9, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it is changing its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open on Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The rebranding and ti

    3/9/26 8:30:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR

    Transaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company to rebrand as Greenland MinesCHARLOTTE, N.C. and NUUK, Greenland, March 4, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces the acquisition of Greenland Mines Corp. ("Greenland Mines" or "GMC"), a privately held Delaware corporation that controls an 80% interest in, and an option to acquire the remaining 20% of, the Skaergaard Project in Southeast Greenland — one of the largest and most significant undeveloped palladium, gold, and platinum

    3/4/26 8:00:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Leblanc Jeff was granted 2,500,000 shares, increasing direct ownership by 272% to 3,420,342 units (SEC Form 4)

    4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

    3/6/26 4:12:10 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director El-Dada Riad Hussein was granted 350,000 shares (SEC Form 4)

    4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

    3/6/26 4:02:24 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Zentman Samuel M was granted 350,000 shares, increasing direct ownership by 48% to 1,086,440 units (SEC Form 4)

    4 - Klotho Neurosciences, Inc. (0001907223) (Issuer)

    3/6/26 3:58:02 PM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLTO
    Leadership Updates

    Live Leadership Updates

    View All

    Klotho Neurosciences Completes Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML

    Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it changed its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open today, Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The Company will hol

    3/12/26 10:27:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Klotho Neurosciences Announces Rebranding to Greenland Mines Ltd and Change of Nasdaq Ticker Symbol to GRML Effective March 12, 2026

    Company to hold investor webcast on March 12, 2026 at 4:15PM ET to discuss its expanded focus on critical minerals development in Greenland CHARLOTTE, N.C., March 9, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces that it is changing its corporate name to Greenland Mines Ltd and its stock ticker to "GRML" effective at market open on Thursday, March 12, 2026. No action will be required by existing shareholders — shares held in brokerage accounts will be automatically updated to reflect the new symbol. The rebranding and ti

    3/9/26 8:30:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences' Scientific Advisory Board

    NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer's and Parkinson's disease is proud to announce the appointment of Dr. Merit Cudkowicz, MD, MSc, to its Scientific Advisory Board (SAB). Dr. Cudkowicz is the Chair of Neurology at MGH, Director of the Sean M. Healey & AMG Center for ALS, and is the Julieanne Dorn Professor of Neurology at Harvard Medical School. A member of the National Academy of Medicine, Dr. Cudkowicz has been a leading clinician in promoting and devising more efficient methods for the development of thera

    12/9/24 11:00:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KLTO
    Financials

    Live finance-specific insights

    View All

    KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR

    Transaction delivers shareholders direct ownership in one of the largest undeveloped palladium-gold deposits on Earth, establishing a new western champion in critical mineral supply security; Company to rebrand as Greenland MinesCHARLOTTE, N.C. and NUUK, Greenland, March 4, 2026 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) ("Klotho" or the "Company") today announces the acquisition of Greenland Mines Corp. ("Greenland Mines" or "GMC"), a privately held Delaware corporation that controls an 80% interest in, and an option to acquire the remaining 20% of, the Skaergaard Project in Southeast Greenland — one of the largest and most significant undeveloped palladium, gold, and platinum

    3/4/26 8:00:00 AM ET
    $KLTO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care